Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Otten, M.H.; Prince, F.H.M.; Twilt, M.; Rossum, M.A.J. van; Armbrust, W.; Hoppenreijs, E.P.A.H.; ... ; Suijlekom-Smit, L.W.A. van (2010)

Article / Letter to editor

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

• JUVENILE IDIOPATHIC ARTHRITIS ANTIRHEUMATIC AGENTS TUMOR NECROSIS FACTOR-alpha DRUG ADMINISTRATION SCHEDULE TREATMENT OUTCOME ARTHRITIS rheumatoid-arthritis efficacy children therapy safety

• All authors: Otten, M.H.; Prince, F.H.M.; Twilt, M.; Rossum, M.A.J. van; Armbrust, W.; Hoppenreijs, E.P.A.H.; Kamphuis, S.; Koopman-Keemink, Y.; Wulffraat, N.M.; Gorter, S.L.; Cate, R. ten; Suijlekom-Smit, L.W.A. van
• Date: 2010-03-31
• Journal: Journal of Rheumatology
• Volume: 37
• Issue: 3
• Pages: 665 - 667
• DOI: doi:10.3899/jrheum.090550